Ambient air pollution has gained recognition as an important source of cardiovascular morbidity and mortality ([@b5-ehp-117-1287]; [@b10-ehp-117-1287]; [@b29-ehp-117-1287]). In addition to long-term mortality, daily fluctuations in fine particles \[particulate matter with median aerodynamic diameter \< 2.5 μm (PM~2.5~)\] and ozone have been linked to short-term cardiovascular and pulmonary mortality ([@b2-ehp-117-1287]; [@b5-ehp-117-1287]; [@b11-ehp-117-1287]). Studies in subjects with implanted cardioverter defibrillators demonstrating an association between PM~2.5~ elevation and increased incidence of ventricular arrhythmias and rapid atrial fibrillation suggest autonomic dysregulation as a putative pathway to these clinical end points ([@b9-ehp-117-1287]; [@b27-ehp-117-1287]; [@b32-ehp-117-1287]). The role of PM~2.5~-mediated autonomic dysregulation has been explored using heart rate variability (HRV) as a surrogate for autonomic tone ([@b35-ehp-117-1287]) in epidemiologic studies ([@b6-ehp-117-1287]; [@b15-ehp-117-1287]; [@b22-ehp-117-1287]; [@b23-ehp-117-1287]), animal studies ([@b14-ehp-117-1287]), and human experimental studies ([@b8-ehp-117-1287]; [@b17-ehp-117-1287]). Yet there is still a scarcity of knowledge about health effects of potential synergy between PM~2.5~ and ambient gaseous copollutants ([@b26-ehp-117-1287]). Of these copollutants, O~3~ interaction is of particular interest given its possible role in local oxidation, creation of free radicals, and potentiation of pollutant deposition onto surfaces ([@b12-ehp-117-1287]; [@b25-ehp-117-1287]).

To assess whether the association between particulate exposure and autonomic function is altered by concomitant O~3~, we conducted a randomized, single-blind, crossover study, with subjects undergoing exposure to concentrated ambient particles (CAPs), O~3~, combined CAPs and O~3~, and filtered air. Secondary aims of the study included assessing for a dose--response relationship for CAPs exposure both with and without O~3~, assessing blood pressure (BP) response to exposures, and assessing whether a subgroup of subjects with asthma was more susceptible to autonomic dysregulation after exposures.

Materials and Methods
=====================

Study population
----------------

The study was approved by the Human Subjects Review Committee of the University of Toronto and was performed at the Gage Occupational and Environmental Health Unit in Toronto, Ontario, Canada. Informed consent was obtained from 50 male and female nonsmoking subjects, 19--48 years of age, without any history of cardiovascular disease or risk factors. Subjects were pooled from two separate studies, study A and study B. One subject participated in both studies.

From July 1999 through February 2003, study A conducted exposures on subjects with and without asthma (*n* = 21). Asthmatic status was determined by physician diagnosis and confirmed by methacholine challenge. Asthmatic subjects had been off of any short-acting bronchodilators from midnight onward and off of corticosteroid treatment for at least 1 month before all visits. Study B was conducted from January 2004 through October 2007, and included only subjects without asthma (*n* = 30). BP responses to exposure in study B have been reported previously ([@b36-ehp-117-1287]).

Exposure protocol
-----------------

All subjects were intended to receive four 2-hr exposures in random order as follows: *a*) sham filtered air (FA) with particles removed by a high-efficiency particulate arrester (HEPA) filter and no added O~3~; *b*) CAPs with target PM~2.5~ mass concentration of 150 μg/m^3^; *c*) O~3~ with target concentration of 120 ppb; and *d*) CAPs + O~3~. In addition, a subset of participants in study A underwent additional exposures with a target CAPs mass concentration of 60 μg/m^3^. Exposures within the same subject were separated by at least 2 weeks, and all exposures were conducted at the same time of day to avoid confounding by circadian variations ([@b4-ehp-117-1287]; [@b35-ehp-117-1287]). In addition, subjects were seated at rest in the exposure chamber 15 min before receiving the intended exposure to allow for acclimation to sitting in the chamber.

Details of the human exposure facility have been described previously ([@b4-ehp-117-1287]; [@b28-ehp-117-1287]; [@b37-ehp-117-1287]). Briefly, ambient particles with aerodynamic diameter \< 2.5 μm were drawn through an inlet outside of the laboratory, concentrated using a Harvard virtual impactor ([@b34-ehp-117-1287]), diluted to the target concentration, and delivered via facemask to subjects seated at rest inside an enclosure ([@b28-ehp-117-1287]). The achieved CAPs mass concentration was measured gravimetrically from samples obtained via a port proximal to the facemask ([@b28-ehp-117-1287]). The concentrator was run during the non-CAPs exposures, but particles were removed with a HEPA filter proximal to the facemask ([@b28-ehp-117-1287]; [@b36-ehp-117-1287]). O~3~ was produced with an arc generator using medical-grade oxygen and delivered upstream of the particle concentrator. O~3~ concentration was maintained at approximately 120 ppb measured just upstream of the facemask by an O~3~ analyzer (model 1008-RS; Dasibi Environmental, Glendale, CA, USA). Ambient temperature, relative humidity, and ambient gaseous pollutant concentrations including carbon monoxide, carbon dioxide, sulfur dioxide, nitrogen oxide, and nitrogen dioxide were monitored during the exposure as previously described ([@b28-ehp-117-1287]; [@b36-ehp-117-1287]). In addition, CAPs mass concentration was continuously monitored using a tapered element oscillating microbalance monitor (TEOM) (model 1400a; Rupprecht & Patashnick Co. Inc., Albany, NY, USA).

Outcome measurement
-------------------

The primary outcome measure was change in several HRV indices between the start and end of each 2-hr exposure ([Figure 1](#f1-ehp-117-1287){ref-type="fig"}). Electrocardiograms were continuously recorded using digital Holter monitors (Marquette Medical Systems, Milwaukee, WI, USA) and subsequently stored and analyzed on a Marquette Medical Systems (MARS) Unity workstation. Beat annotations were automatically assigned by the software and reviewed by an investigator blinded to the exposure status.

Calculations for time domain \[standard deviation of NN intervals (SDNN); square root of the mean squared differences of successive NN intervals (rMSSD); proportion of successive NN intervals with differences \> 50 msec (pNN50)\] and frequency domain \[low-frequency (LF) power (0.04--0.15 Hz), high-frequency (HF) power (0.04--0.15 Hz), and their ratio (LF/HF)\] HRV parameters were evaluated on 5-min intervals of ECG data using standard techniques ([@b35-ehp-117-1287]). Only normal sinus beats were used. These measures were calculated at 0, 30, 60, 90, and 120 min into the exposure ([Figure 1](#f1-ehp-117-1287){ref-type="fig"}). For intervals with \< 90% valid quality recording, the previous 5-min window was used instead.

In addition, systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured every 30 min throughout the 2-hr exposure ([Figure 1](#f1-ehp-117-1287){ref-type="fig"}) using a calibrated and automated sphygmomanometer (Oscar-1 or Oscar-2; SunTech Medical Instruments, Inc., Raleigh, NC, USA). Where the data were available, the analysis used a mean of three successive BP measurements at each time point. We also included mean arterial pressure (MAP) in our measurements, defined as the weighted average (2:1) of DBP and SBP. Furthermore, minute ventilation and respiratory frequency were recorded every 30 min during the exposure using a turbine-type flow transducer (VMM401; Interface Associates, Aliso Viejo, CA, USA).

Statistical analysis
--------------------

We used linear mixed-effects models to evaluate the effects of exposure while accounting for the correlation between multiple measurements within each individual. In a first analysis, models included fixed effects for exposure (in four categories: FA, CAPs, O~3~, and CAPs + O~3~), age (linear continuous), sex, and asthmatic status (yes/no), and a random-subject intercept, modeling the primary outcome of change in HRV or BP between start and end of exposure as linear continuous variables. In a second analysis, we entered average measured CAPs mass concentration into the model as a linear continuous-exposure variable and stratified the CAPs dose--response analysis by presence or absence of O~3~.

We conducted several sensitivity analyses to evaluate the robustness of our main results. First, to assess whether additional time points of HRV and BP data would improve the resolution of the models, we modeled the mean change in outcome across five measurements taken every 30 min during the 2-hr exposure. Second, we evaluated whether the responses to CAPs and O~3~ differed in asthmatics versus non-asthmatics by adding exposure-by-asthmatic status interactions to the main model. Third, we controlled for potential confounding by minute ventilation and respiratory frequency, which can especially affect HF HRV ([@b19-ehp-117-1287]; [@b35-ehp-117-1287]). Fourth, we added average heart rate from the prior 5-min interval as a fixed effect.

All hypothesis tests were two-sided, and *p* \< 0.05 was considered statistically significant. We used the SAS statistical analysis package (version 9.1; SAS Institute, Cary, NC, USA) for all analyses. Regression diagnostics were performed to verify model assumptions.

Results
=======

Subject characteristics and exposures
-------------------------------------

A total of 50 subjects with complete Holter data were included from both studies in the analyses ([Table 1](#t1-ehp-117-1287){ref-type="table"}). The main distinction between study A and study B was the inclusion of 10 mildly asthmatic subjects in study A. The number of exposures with complete Holter data in each exposure category was as follows: 53 exposures to CAPs; 53 exposures to CAPs + O~3~; 40 exposures to O~3~; and 42 exposures to FA (sham). By design, a subset of participants in study A underwent additional exposures to CAPs at a lower target concentration, resulting in relatively fewer FA- and O~3~-only exposures. The mean CAPs mass concentration was 121.6 ± 48.0 μg/m^3^ ([Figure 2](#f2-ehp-117-1287){ref-type="fig"}). The mean O~3~ concentration was 113.9 ± 6.6 ppb. During FA exposure, the mean CAPs mass and O~3~ concentrations were 2.3 ± 5.7 μg/m^3^ and 10.0 ± 7.4 ppb, respectively.

Outcomes
--------

### Heart rate variability

As illustrated in [Figure 3](#f3-ehp-117-1287){ref-type="fig"}, for all of the exposures, subjects had a net increase in SDNN as the 2-hr exposure progressed. The trend with time was similar for the other indices of HRV. The primary analysis, change in HRV indices between the start and end of the 2-hr exposure period, yielded no consistent differences between the exposure categories ([Table 2](#t2-ehp-117-1287){ref-type="table"}). HF HRV showed a statistically significant increase for the CAPs-only exposure (*p* = 0.046) and a similar trend for O~3~ exposure (*p* = 0.051) when compared with filtered air. Sensitivity analyses separately incorporating minute ventilation, respiratory frequency, average heart rate, or the asthma interaction term into the main model abolished this difference and did not materially alter findings for the other HRV outcomes. Analyses using the mean of all five HRV measurements during the 2-hr exposure or assessing change in HRV by minutes into exposure did not materially alter our conclusions. We did not find evidence of heterogeneity by asthmatic status.

We also analyzed the dose--response relationship between CAPs mass concentration and change in the HRV indices, stratified by presence or absence of O~3~. For those exposures without O~3~ (i.e., CAPs alone and FA), there was no significant dose--response relationship between gravimetric CAPs mass concentration and any measure of HRV. However, when analyzing the CAPs mass concentration relationship for exposures with O~3~ (i.e., CAPs + O~3~ and O~3~ alone), there was a suggestion of negative dose--response slopes ([Table 3](#t3-ehp-117-1287){ref-type="table"}) between CAPs mass concentration and several HRV indices. This trend was seen in SDNN, rMSSD, and HF and was statistically significant for LF (*p* = 0.02).

### Blood pressure

A statistically significant increase in DBP for CAPs + O~3~ relative to FA was previously reported for the subjects in study B ([@b37-ehp-117-1287]). Therefore, in the current analysis, we focused only on the BP data from study A.

We assessed the change in BP between the start and end of the the 2-hr exposure ([Table 4](#t4-ehp-117-1287){ref-type="table"}) as well as the change in BP at each 30-min interval. Similar to data from study B, subjects in study A demonstrated a statistically significant increase in DBP (1.97 mmHg, *p* = 0.02) in response to CAPs + O~3~. [Figure 4](#f4-ehp-117-1287){ref-type="fig"} shows DBP at 30-min intervals throughout the exposure period. All the subjects experienced an equilibration period after entering the chamber when their DBP decreased initially with time. After this equilibration, the CAPs + O~3~ exposure began to diverge from the other exposures, demonstrating a statistically significant increase relative to filtered air at 60 min (*p* \< 0.03). No clear pattern emerged among the exposures for SBP and MAP, although SBP tended to decrease in the O~3~-only exposure ([Table 4](#t4-ehp-117-1287){ref-type="table"}).

Sensitivity analyses additionally controlling for minute ventilation, respiratory frequency, or heart rate did not materially alter the results. We did not find evidence of heterogeneity of effect by asthmatic status.

Discussion
==========

To our knowledge, this is the largest study assessing the acute impact of CAPs exposure on HRV in young healthy adults. In addition, with recent evidence in animals showing effects of combined O~3~ and particulate exposure on HRV ([@b18-ehp-117-1287]), this is also the largest human controlled-exposure study looking at the impact of combined exposure to CAPs and O~3~ on HRV.

In this study, HRV indices were used as surrogate markers of autonomic tone ([@b35-ehp-117-1287]). The time-domain measures rMSSD and pNN50 are thought to reflect parasympathetic influences, whereas SDNN may also have sympathetic influence ([@b7-ehp-117-1287]; [@b19-ehp-117-1287]; [@b35-ehp-117-1287]). Among the frequency-domain parameters, HF almost exclusively reflects parasympathetic influence and respiratory variation ([@b19-ehp-117-1287]; [@b35-ehp-117-1287]). Interpreting changes in LF and LF/HF is controversial; LF may to some extent reflect sympathetic influences, whereas LF/HF possibly reflects sympathovagal balance ([@b35-ehp-117-1287]).

There is a large body of evidence suggesting that cardiovascular response to pollutants varies with age and comorbidities ([@b5-ehp-117-1287]; [@b10-ehp-117-1287]; [@b16-ehp-117-1287]; [@b20-ehp-117-1287]). In this group of young healthy adult subjects, we did not detect a consistent pattern for changes in HRV indices among the exposure categories. HF had a statistically significant difference in some of the exposures relative to filtered air. However, given that HF is particularly sensitive to respiratory variation ([@b35-ehp-117-1287]), adjusting for respiratory parameters abolished this difference. Despite the absence of a clear pattern of difference in the categorical exposure models, the dose--response analysis in the setting of concomitant O~3~ demonstrated a trend toward negative linear association between CAPs mass concentration and change in several HRV indices, with a statistically significant relationship for LF HRV. No such relationship existed without O~3~ present. Our findings for CAPs alone agree with findings in other studies reporting the lack of significant effect of CAPs alone on HRV in young healthy subjects, despite significant effects noted in elderly subjects ([@b8-ehp-117-1287]; [@b17-ehp-117-1287]). The suggestion of dose--response CAPs effects in the presence of O~3~ is of import, given emerging research priorities emphasizing studies of copollutants and dose--response relationships ([@b26-ehp-117-1287]).

Our results corroborate previous findings of increase in DBP with CAPs + O~3~ ([@b37-ehp-117-1287]). The effect became statistically significant at 60 min and became more pronounced toward the end of the exposure. With regard to SBP, only one human controlled-exposure study ([@b17-ehp-117-1287]) has demonstrated modest changes with CAPs exposure, whereas other studies have not shown effects ([@b8-ehp-117-1287]; [@b37-ehp-117-1287]). In one exposure study conducted in canines exposed to CAPs, the increase in DBP was of greater magnitude than the increase in SBP ([@b1-ehp-117-1287]). One possible explanation for the apparent disparity between SBP and DBP change in our study is the attenuation of peripheral SBP amplification in young adults ([@b13-ehp-117-1287]). It has been shown in adults \< 50 years of age that for a given increase in central and peripheral DBP, peripherally measured SBP does not increase in parallel as it does for older adults ([@b38-ehp-117-1287]). Alternatively, the baseline increase in SBP in our filtered-air control group and the greater variation and lability of SBP measurements relative to DBP in our study may have made it more difficult to appreciate a meaningfully different change in SBP.

The effects of CAPs + O~3~ on BP, and possibly in a dose--response fashion on HRV, raise important questions about the interaction and possible synergy between the two components in their impact on cardiovascular physiology. With regard to possible mechanisms for pollutant-mediated changes in systemic physiology, it has been demonstrated in animal models that O~3~ exposure leads to lung hyperpermeability ([@b21-ehp-117-1287]), possibly increasing systemic toxin absorption or increasing local inflammation. Other possibilities include O~3~-mediated free radical production or conversion of particles to compounds with greater tendency to deposit on surfaces, the latter having been demonstrated with ammonium nitrate particles ([@b25-ehp-117-1287]). In humans, generated ammonium nitrate particle with O~3~ combination exposure has recently been shown to suppress HRV ([@b31-ehp-117-1287]). The changes in DBP may be related to changes in autonomic tone, as shown in cohort studies demonstrating correlation among HRV measures and incident hypertension ([@b33-ehp-117-1287]), but the data in our study do not consistently validate this hypothesis. Alternatively, the DBP response may be related to direct vasoconstriction ([@b4-ehp-117-1287]; [@b36-ehp-117-1287], [@b37-ehp-117-1287]) or increased peripheral vascular resistance independent of autonomic changes, but we did not directly test this hypothesis in this study.

Our study has several potential limitations that need to be considered. First, we could not control for ambient pollutant exposure prior to each visit. Future studies may address this limitation with personal monitoring, detailed time--activity diaries, or optimally, having study participants sleep onsite the night preceding any experiments. Second, because the study was designed to examine acute effects, we could not assess more prolonged time-dependent effects of exposures ([@b24-ehp-117-1287]) or effects resulting from sequential rather than concomitant exposures. Future studies may address this limitation using staggered and/or prolonged exposures. Third, because our particle concentrator does not concentrate particles \< 0.1 μm, limiting particle size to predominantly accumulation mode, we could not assess the role of ultrafine particles. Controlled-exposure studies comparing the toxicity of ultrafine, fine, and coarse particles in humans are clearly needed. Fourth, we did not measure or remove volatile organic compounds, which likely have independent effects ([@b3-ehp-117-1287]). However, the crossover design of this study reduced potential confounding either by exposure variation or by other unmeasured confounders.

An important strength of this study is that CAPs exposures were derived from real-world ambient particles from an urban environment. According to one sampling campaign in 1997 through 1999, PM~2.5~ in Toronto typically includes approximately one-quarter organic carbon, similar portions sulfates, nitrates, ammonium, and black carbon, and small portions of soil or other constituents ([@b3-ehp-117-1287]). The large sample size of our study and the fact that composition of CAPs changes daily in these experiments can be exploited in future analyses to identify components or constituents of CAPs that may be associated with greater effects.

Conclusion
==========

In summary, ambient PM~2.5~ has been shown to impact HRV in epidemiologic studies of populations considered vulnerable on the basis of age or chronic diseases ([@b6-ehp-117-1287]; [@b15-ehp-117-1287]; [@b22-ehp-117-1287]; [@b23-ehp-117-1287]; [@b30-ehp-117-1287]). Whereas most epidemiologic studies focus on effects ranging from several hours to days ([@b6-ehp-117-1287]; [@b22-ehp-117-1287]; [@b23-ehp-117-1287]; [@b30-ehp-117-1287]), we attempted to study acute effects within the span of 2 hr. Our data suggest that in younger subjects, CAPs alone does not produce significant effects, but when combined with O~3~, there is an increase in DBP that may be mediated through autonomic changes. The possibility of an autonomic effect is suggested in the dose--response relationship of HRV to CAPs mass concentration, although this is of small magnitude and borderline statistical significance in this group of young healthy adult subjects. Given that CAPs alone produce HRV changes in more vulnerable populations ([@b6-ehp-117-1287]; [@b8-ehp-117-1287]; [@b15-ehp-117-1287]; [@b22-ehp-117-1287]; [@b23-ehp-117-1287]; [@b30-ehp-117-1287]), elderly subjects or subjects with comorbidities may experience even stronger synergistic effects with simultaneous controlled exposure to CAPs and O~3~.
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###### 

Baseline subject characteristics and exposure data.

  Characteristic                            Overall                                          Study A          Study B
  ----------------------------------------- ------------------------------------------------ ---------------- ----------------
  No. of subjects                           50[a](#tfn1-ehp-117-1287){ref-type="table-fn"}   21               30
  Age \[years, mean ± SD (range)\]          27.08 ± 7.13 (19--48)                            27.29 ± 5.60     26.93 ± 8.13
  Male \[no. (%)\]                          24 (47)                                          9 (43)           15 (50)
  Ethnicity \[no. (%)\]                                                                                       
   White                                    24 (49)                                          10 (48)          14 (50)
   Black                                    7 (7)                                            4 (19)           3 (11)
   Asian                                    16 (33)                                          6 (29)           10 (36)
   Other                                    2 (4)                                            1 (5)            1 (4)
  Body mass index \[kg/m^2^ (mean ± SD)\]   22.72 ± 3.24                                     22.35 ± 2.47     23.22 ± 3.54
  Medical history                                                                            10 Asthmatics    None
  CAPs \[μg/m^3^ (mean ± SD)\]              127.03 ± 62.13                                   101.16 ± 42.43   146.20 ± 67.58
  O~3~ \[ppb (mean ± SD)\]                  113.86 ± 6.62                                    118.69 ± 3.31    110.30 ± 6.19

One subject was included in both studies.

###### 

Change in HRV (± SE) between start and end of 2-hr exposure period.

  HRV variable/Exposure             ΔPre- and postexposure   *p*-Value[a](#tfn2-ehp-117-1287){ref-type="table-fn"}
  --------------------------------- ------------------------ -------------------------------------------------------
  Δ5-Min average heart rate (bpm)                            
   FA                               2.57 ± 0.91              
   CAPs                             2.09 ± 0.93              0.61
   O~3~                             1.55 ± 0.95              0.28
   CAPs + O~3~                      2.04 ± 1.09              0.62
  ΔSDNN (msec)                                               
   FA                               22.14 ± 4.87             
   CAPs                             26.31 ± 5.10             0.41
   O~3~                             34.29 ± 7.30             0.098
   CAPs + O~3~                      17.74 ± 4.29             0.31
  ΔrMSSD (msec)                                              
   FA                               −4.70 ± 6.28             
   CAPs                             5.51 ± 7.74              0.19
   O~3~                             16.77 ± 11.92            0.07
   CAPs + O~3~                      −0.12 ± 6.79             0.50
  ΔpNN50 (%)                                                 
   FA                               −1.48 ± 2.01             
   CAPs                             0.25 ± 1.74              0.32
   O~3~                             1.28 ± 2.32              0.24
   CAPs + O~3~                      −1.18 ± 2.33             0.90
  ΔLF (msec^2^)                                              
   FA                               456 ± 449                
   CAPs                             1381 ± 671               0.17
   O~3~                             1915 ± 1167              0.21
   CAPs + O~3~                      482 ± 474                0.96
  ΔHF (msec^2^)                                              
   FA                               −149 ± 198               
   CAPs                             348 ± 247                0.046
   O~3~                             467 ± 312                0.051
   CAPs + O~3~                      21 ± 239                 0.48
  ΔLF/HF ratio                                               
   FA                               0.73 ± 0.45              
   CAPs                             0.62 ± 0.55              0.84
   O~3~                             0.52 ± 0.56              0.70
   CAPs + O~3~                      0.12 ± 0.62              0.33

Compared with exposure to filtered air.

###### 

Dose--response slope for CAPs mass concentration versus 2-hr change in HRV.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  HRV measure                 Exposure    Slope[a](#tfn3-ehp-117-1287){ref-type="table-fn"}   SE      *p*-Value[b](#tfn4-ehp-117-1287){ref-type="table-fn"}   *p*-Contrast[c](#tfn5-ehp-117-1287){ref-type="table-fn"}
  --------------------------- ----------- --------------------------------------------------- ------- ------------------------------------------------------- ----------------------------------------------------------
  Δ5-min\                     No O~3~     −0.033                                              0.060   0.58                                                    
   average heart rate (bpm)                                                                                                                                   

  With O~3~                   0.014       0.057                                               0.80    0.56                                                    

                                                                                                                                                              

  ΔSDNN (msec)                No O~3~     −0.0033                                             0.39    0.99                                                    

                              With O~3~   −0.84                                               0.37    0.03                                                    0.12

                                                                                                                                                              

  ΔrMSSD (msec)               No O~3~     0.38                                                0.59    0.52                                                    

                              With O~3~   −0.96                                               0.56    0.09                                                    0.10

                                                                                                                                                              

  ΔpNN50 (%)                  No O~3~     0.08                                                0.13    0.53                                                    

                              With O~3~   −0.13                                               0.12    0.28                                                    0.23

                                                                                                                                                              

  ΔLF (msec^2^)               No O~3~     80.38                                               55.71   0.15                                                    

                              With O~3~   −94.51                                              52.53   0.074                                                   0.02

                                                                                                                                                              

  ΔHF (msec^2^)               No O~3~     18.97                                               17.57   0.28                                                    

                              With O~3~   −22.19                                              16.63   0.18                                                    0.09

                                                                                                                                                              

  ΔLF/HF ratio                No O~3~     0.0048                                              0.034   0.89                                                    

                              With O~3~   −0.034                                              0.032   0.29                                                    0.41
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Slopes reported for a 10-μg/m^3^ change in CAPs mass concentration.

*p*-Homogeneity.

*p*-Contrast between slope with O~3~ and slope without O~3~.

###### 

Change in BP between exposure start and exposure end.

  BP measure/exposure   ΔBP ± SE       *p-*Value[a](#tfn6-ehp-117-1287){ref-type="table-fn"}
  --------------------- -------------- -------------------------------------------------------
  ΔSBP (mmHg)                          
   FA                   2.32 ± 1.79    
   CAPs                 0.04 ± 2.51    0.37
   O~3~                 −1.18 ± 1.96   0.07
   CAPs + O~3~          0.90 ± 2.00    0.48
  ΔDBP (mmHg)                          
   FA                   −0.84 ± 1.20   
   CAPs                 −0.87 ± 1.43   0.98
   O~3~                 −0.23 ± 1.57   0.70
   CAPs + O~3~          1.97 ± 1.21    0.02
  ΔMAP                                 
   FA                   0.17 ± 1.21    
   CAPs                 −0.62 ± 1.65   0.63
   O~3~                 −0.56 ± 1.48   0.62
   CAPs + O~3~          1.64 ± 1.15    0.20

Compared with exposure to filtered air.
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